Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia

Completed · Phase 3

Conditions studied: Dyspepsia

In brief

This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.

Key facts

Study ID

NCT00232102

Run by

Novartis

People needed

423

Starts

2004-09-01

Expected to finish

2006-08-01

Last updated by the study team

2008-02-01

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female, 18 years and older
• Fulfilled eligibility criteria in CHTF919 D2302 (double blind study) and successfully completed the double-blind study

You may not qualify if…

• Early discontinuation from the double-blind study
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Novartis — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.